Sign in
4

Changes in Ownership

HALOZYME THERAPEUTICS, INC. Filed Acc 0001415889-24-023657

SVP, CHIEF TECHNICAL OFFICER sold 20,000 shares at an average $62.45 ($1,249,096)

  • SVP, CHIEF TECHNICAL OFFICER acquired 20,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-17 Option exercise 10b5-1 +10,000 $16.65 $166,500 183,756 D
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-17 Sale 10b5-1 −10,000 $62.88 $628,780 173,756 D
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-18 Option exercise 10b5-1 +10,000 $16.65 $166,500 183,756 D
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-18 Sale 10b5-1 −7,963 $61.89 $492,838 175,793 D
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-18 Sale 10b5-1 −2,037 $62.58 $127,477 173,756 D
Derivatives
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-17 Option exercise · Option to Purchase Common Stock 10b5-1 −10,000 21,861 D
LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER 2024-09-18 Option exercise · Option to Purchase Common Stock 10b5-1 −10,000 11,861 D
Open-market sales · 20,000 sh · avg $62.45 · $1,249,096
Loading xslF345X05/form4-09182024_100954.xml…